Patents by Inventor Kazufumi Honda
Kazufumi Honda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11733250Abstract: The purpose of the present invention is to provide a simple and highly accurate method for detecting pancreatic exocrine dysfunction with minimal invasiveness to a subject. The method comprising in vitro measurement of two APOA2 protein variants, mutants thereof and/or fragments thereof in a body fluid sample derived from the subject and detection of the presence or absence of pancreatic exocrine dysfunction on the basis of the measured amounts, and a detection kit for pancreatic exocrine dysfunction including antibodies that can specifically bind to said proteins are provided.Type: GrantFiled: September 28, 2021Date of Patent: August 22, 2023Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Michimoto Kobayashi, Mitsuaki Sanada, Yoshiyuki Sasajima, Giman Jung, Tesshi Yamada, Kazufumi Honda
-
Publication number: 20220120752Abstract: The present invention provides a method for detecting biliary tract cancer by measuring the amounts of APOA2 protein variants in a test sample with anti-APOA2 antibodies, the anti-APOA2 antibodies for use in the above method and a detection kit for biliary tract cancer including the above antibodies.Type: ApplicationFiled: December 28, 2021Publication date: April 21, 2022Applicants: Toray Industries, Inc., NATIONAL CANCER CENTERInventors: Mitsuaki Sanada, Michimoto Kobayashi, Aiko Takayama, Yoshiyuki Sasajima, Giman Jung, Tesshi Yamada, Kazufumi Honda
-
Patent number: 11231423Abstract: The present invention provides a method for detecting biliary tract cancer by measuring the amounts of APOA2 protein variants in a test sample with anti-APOA2 antibodies, the anti-APOA2 antibodies for use in the above method and a detection kit for biliary tract cancer including the above antibodies.Type: GrantFiled: January 25, 2016Date of Patent: January 25, 2022Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Mitsuaki Sanada, Michimoto Kobayashi, Aiko Takayama, Yoshiyuki Sasajima, Giman Jung, Tesshi Yamada, Kazufumi Honda
-
Publication number: 20220011322Abstract: The purpose of the present invention is to provide a simple and highly accurate method for detecting pancreatic exocrine dysfunction with minimal invasiveness to a subject. The method comprising in vitro measurement of two APOA2 protein variants, mutants thereof and/or fragments thereof in a body fluid sample derived from the subject and detection of the presence or absence of pancreatic exocrine dysfunction on the basis of the measured amounts, and a detection kit for pancreatic exocrine dysfunction including antibodies that can specifically bind to said proteins are provided.Type: ApplicationFiled: September 28, 2021Publication date: January 13, 2022Applicants: Toray Industries, Inc., NATIONAL CANCER CENTERInventors: Michimoto Kobayashi, Mitsuaki Sanada, Yoshiyuki Sasajima, Giman Jung, Tesshi Yamada, Kazufumi Honda
-
Patent number: 11162956Abstract: The purpose of the present invention is to provide a simple and highly accurate method for detecting pancreatic exocrine dysfunction with minimal invasiveness to a subject. The method comprising in vitro measurement of two APOA2 protein variants, mutants thereof and/or fragments thereof in a body fluid sample derived from the subject and detection of the presence or absence of pancreatic exocrine dysfunction on the basis of the measured amounts, and a detection kit for pancreatic exocrine dysfunction including antibodies that can specifically bind to said proteins are provided.Type: GrantFiled: March 1, 2016Date of Patent: November 2, 2021Assignees: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Michimoto Kobayashi, Mitsuaki Sanada, Yoshiyuki Sasajima, Giman Jung, Tesshi Yamada, Kazufumi Honda
-
Publication number: 20180031574Abstract: The purpose of the present invention is to provide a simple and highly accurate method for detecting pancreatic exocrine dysfunction with minimal invasiveness to a subject. The method comprising in vitro measurement of two APOA2 protein variants, mutants thereof and/or fragments thereof in a body fluid sample derived from the subject and detection of the presence or absence of pancreatic exocrine dysfunction on the basis of the measured amounts, and a detection kit for pancreatic exocrine dysfunction including antibodies that can specifically bind to said proteins are provided.Type: ApplicationFiled: March 1, 2016Publication date: February 1, 2018Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Michimoto Kobayashi, Mitsuaki Sanada, Yoshiyuki Sasajima, Giman Jung, Tesshi Yamada, Kazufumi Honda
-
Publication number: 20180017564Abstract: The present invention provides a method for detecting biliary tract cancer by measuring the amounts of APOA2 protein variants in a test sample with anti-APOA2 antibodies, the anti-APOA2 antibodies for use in the above method and a detection kit for biliary tract cancer including the above antibodies.Type: ApplicationFiled: January 25, 2016Publication date: January 18, 2018Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Mitsuaki Sanada, Michimoto Kobayashi, Aiko Takayama, Yoshiyuki Sasajima, Giman Jung, Tesshi Yamada, Kazufumi Honda
-
Patent number: 9644026Abstract: An antibody against mutant ?-actinin-4 having an amino acid sequence with at least one amino acid residue substitution in the region between position 245 and 263 in the amino acid sequence of ?-actinin-4, wherein the antibody recognizes all or a part of the substituted amino acid residue(s) in the region.Type: GrantFiled: September 9, 2011Date of Patent: May 9, 2017Assignees: TRANS GENIC INC., NATIONAL CANCER CENTERInventors: Shingo Shinagawa, Kazunari Ito, Yoshimi Tokashiki, Tomoaki Miyamoto, Kazufumi Honda, Tesshi Yamada
-
Publication number: 20160245815Abstract: It is intended to provide a method for detecting a pancreatic tumor (pancreatic cancer or benign pancreatic tumor) with low invasiveness to a test subject and with high detection sensitivity and accuracy. The present invention provides a method for detecting a pancreatic tumor by measuring the amounts of APOA2 protein variants in a sample of a test subject using anti-APOA2 antibodies, anti-APOA2 antibodies for use in the method, and a kit for the detection of a pancreatic tumor, comprising the antibodies.Type: ApplicationFiled: September 30, 2014Publication date: August 25, 2016Applicants: TORAY INDUSTRIES, INC., NATIONAL CANCER CENTERInventors: Mitsuaki SANADA, Michimoto KOBAYASHI, Aiko TAKAYAMA, Yoshiyuki SASAJIMA, Giman JUNG, Tesshi YAMADA, Kazufumi HONDA
-
Publication number: 20140248261Abstract: An antibody against mutant ?-actinin-4 having an amino acid sequence with at least one amino acid residue substitution in the region between position 245 and 263 in the amino acid sequence of ?-actinin-4, wherein the antibody recognizes all or a part of the substituted amino acid residue(s) in the region.Type: ApplicationFiled: September 9, 2011Publication date: September 4, 2014Applicants: NATIONAL CANCER CENTER, TRANS GENIC INC.Inventors: Shingo Shinagawa, Kazunari Ito, Yoshimi Tokashiki, Tomoaki Miyamoto, Kazufumi Honda, Tesshi Yamada
-
Publication number: 20130137592Abstract: An object of the present invention is to provide biomarkers for predicting response to chemoradiotherapy for cancer and predicting prognosis of a patient with cancer, as well as methods of measuring such biomarkers. The response to chemoradiotherapy for cancer in a vertebrate animal can be predicted by measuring concentrations of a soluble interleukin-6 receptor, MIP-1?, and an activated plasminogen activator inhibitor in the blood obtained from that individual with cancer before treatment with chemoradiotherapy, and prognosis of the same vertebrate animal can be determined by measuring a concentration of soluble interleukin-6 receptor.Type: ApplicationFiled: March 31, 2011Publication date: May 30, 2013Applicant: NATIONAL CANCER CENTERInventors: Kazufumi Honda, Tesshi Yamada, Yosuke Makuuchi, Yoshiaki Osaka, Setsuo Hirohashi
-
Publication number: 20130052207Abstract: A method of detecting a poor-prognosis stage I lung adenocarcinoma in a mammal, comprising a step of measuring the copy number of ACTN4 gene in the cells of the stage I lung adenocarcinoma tissue obtained from the mammal, wherein, when the copy number of the gene exceeds 4, the stage I lung adenocarcinoma in the mammal is predicted to be a poor-prognosis stage I lung adenocarcinoma.Type: ApplicationFiled: March 29, 2011Publication date: February 28, 2013Applicant: JAPAN HEALTH SCIENCES FOUNDATIONInventors: Kazufumi Honda, Tesshi Yamada, Rintaro Noro, Setsuo Hirohashi
-
Publication number: 20120058204Abstract: The present invention relates to a method of identifying an expression level of cystathionine gamma lyase (CTH) in a sample from a subject. The present invention further discloses a method of diagnosing a subject with cancer having risk of resistance to a platinum-based drug. The present invention also discloses a method for improving efficacy of a platinum-based drug in a subject suffering a cancer.Type: ApplicationFiled: September 7, 2011Publication date: March 8, 2012Applicants: NATIONAL CANCER CENTER RESEARCH INSTITUTE, ABNOVA CORPORATIONInventors: Tesshi Yamada, Kazufumi Honda, Wilber Huang
-
Publication number: 20090004671Abstract: Disclosed herein are a pancreatic carcinoma marker protein that is a blood protein having a molecular weight of 28,080±15, 17,272±9, 17,253±9, 8,766±5, or 14,779±8 (m/z) and a method for detecting pancreatic carcinoma using the marker protein as an indicator.Type: ApplicationFiled: January 26, 2006Publication date: January 1, 2009Applicant: Japan Health Sciences FoundationInventors: Tesshi Yamada, Kazufumi Honda, Setsuo Hirohashi